Filing Details

Accession Number:
0001493152-23-017792
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-16 16:16:10
Reporting Period:
2023-05-12
Accepted Time:
2023-05-16 16:16:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1433607 Inspiremd Inc. NSPR Surgical & Medical Instruments & Apparatus (3841) 262123838
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1528577 Paul Stuka C/O Inspiremd, Inc.
4 Menorat Hamaor St.
Tel Aviv L3 6744832
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-05-12 175,000 $1.63 248,534 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series H Warrants to purchase Common Stock Acquisiton 2023-05-12 87,500 $1.63 87,500 $1.38
Common Stock Series I Warrants to purchase Common Stock Acquisiton 2023-05-12 87,500 $1.63 87,500 $1.38
Common Stock Series J Warrants to purchase Common Stock Acquisiton 2023-05-12 87,500 $1.63 87,500 $1.38
Common Stock Series K Warrants to purchase Common Stock Acquisiton 2023-05-12 87,500 $1.63 87,500 $1.38
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
87,500 2023-05-15 No 4 P Indirect
87,500 2023-05-15 No 4 P Indirect
87,500 2023-05-15 No 4 P Indirect
87,500 2023-05-15 No 4 P Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 42,320 Direct
Footnotes
  1. The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").
  2. The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.
  3. These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.
  4. The aggregate number of warrants reported in this row consists of 87,500 Series H Warrants that were acquired in the Private Placement.
  5. The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial.
  6. The aggregate number of warrants reported in this row consists of 87,500 Series I Warrants that were acquired in the Private Placement.
  7. The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm).
  8. The aggregate number of warrants reported in this row consists of 87,500 Series J Warrants that were acquired in the Private Placement.
  9. The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm.
  10. The aggregate number of warrants reported in this row consists of 87,500 Series K Warrants that were acquired in the Private Placement.
  11. The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin.